Most important, low doses of PLK1 kinase inhibitor markedly reduced IL-1β level in both LPS-induced endotoxemia and monosodium urate–induced (MSU-induced) peritonitis models in vivo. Here, IL1B is linked to serum lipopolysaccharide activity.